Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
MDR-TB most commonly develops in the course of TB treatment, [5] and is most commonly due to doctors giving inappropriate treatment, or patients missing doses or failing to complete their treatment. Because MDR tuberculosis is an airborne pathogen, persons with active, pulmonary tuberculosis caused by a multidrug-resistant strain can transmit ...
Patients are often hospitalized for long periods, in isolation. In addition, second-line drugs are extremely expensive compared with the cost of drugs for standard TB treatment. [citation needed] XDR-TB is associated with a much higher mortality rate than MDR-TB, because of a reduced number of effective treatment options. [15] A 2008 study in ...
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, [7] is a contagious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. [1] Tuberculosis generally affects the lungs , but it can also affect other parts of the body. [ 1 ]
Pretomanid is only the third tuberculosis drug to receive approval from the FDA in more than 40 years. [4] [9] The FDA granted pretomanid priority review and orphan drug designations. [4] The FDA granted The Global Alliance for TB Drug Development (TB Alliance) the approval of pretomanid and a tropical disease priority review voucher. [4]
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. [5] For latent tuberculosis, it is often used alone. [4]
Treatment of active TB disease is typically a combination of antibiotics, which results in patients being non-infectious to others usually within a few weeks. Until that point, though, patients can spread TB to others and it’s typically adults with reactivated TB that are the most infectious.